[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644867":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":30,"locations":36,"responsibleParty":65,"collaborators":69,"id":75,"slug":10,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":107,"whyStopped":10,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Institutul Clinic Fundeni","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Euvolemic Hemodialysis Cohort",null,"Participants with end-stage kidney disease on maintenance hemodialysis undergo a structured volume assessment (including clinical assessment, bioimpedance spectroscopy, inferior vena cava measurement, lung ultrasound and echocardiography) and, if necessary, a volume optimization phase. The primary study cohort includes patients who meet predefined euvolemia criteria. An exploratory subgroup includes patients with persistent hypervolemia, analyzed separately.\n\nAdditional invasive evaluation, including right heart catheterization, may be performed only when clinically indicated and is not assigned as a study intervention.",[13],"Other: Observational Assessment",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observational Assessment","Participants undergo structured clinical, echocardiographic, and volume status assessments, including bioimpedance spectroscopy, lung ultrasound and inferior vena cava evaluation. Volume optimization measures are applied as part of routine clinical care and are not assigned as experimental interventions.\n\nRight heart catheterization may be performed in selected patients when clinically indicated and after specific informed consent, and is not considered a study intervention.",[9],[20,24,28],{"name":21,"affiliation":22,"role":23},"Georgiana N Olaru, MD","Institute for Cardiovascular Diseases C.C. Iliescu","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":27},"Gener Ismail, Professor, MD, PhD","Fundeni Clinical Institute","STUDY_CHAIR",{"name":29,"affiliation":22,"role":27},"Ioan M Coman, Professor, MD, PhD",[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Stefan N Lujinschi, MD, PhD candidate","CONTACT","+40728102643","stefanlujinschi@gmail.com",[37,57],{"facility":22,"status":10,"city":38,"state":10,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Bucharest","022322","Romania","RO",{"type":43,"coordinates":44},"Point",[45,46],26.10626,44.43225,{"lat":46,"lon":45},[49,53,54],{"name":50,"role":33,"phone":51,"phoneExt":10,"email":52},"Georgiana Olaru, MD","+40767805197","dr.georgianaolaru@yahoo.com",{"name":50,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Lucian M Predescu, Assist. Prof., MD, PhD","SUB_INVESTIGATOR",{"facility":26,"status":10,"city":38,"state":10,"zip":58,"country":40,"countryCode":41,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"022328",{"type":43,"coordinates":60},[45,46],{"lat":46,"lon":45},[63,64],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},{"name":32,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Stefan Lujinschi","MD, PhD candidate",[70,71,73],{"name":5,"class":6},{"name":72,"class":6},"Carol Davila University of Medicine and Pharmacy",{"name":74,"class":6},"Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu","100644867",false,"NCT07676786","Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients","Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis","EU-PHASE-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* End-stage kidney disease on maintenance HD for ≥ 3 months.\n* Stable clinical condition (no hospitalization in last 30 days).\n* Able and willing to comply with study protocol.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere left-sided valvular disease.\n* Active pulmonary or cardiac decompensation.\n* Persistent hypervolemia after completion of the volume assessment and correction phase\n* Inability to undergo echocardiography or bioimpedance assessment.\n* Acute infection or inflammatory condition at the time of enrollment.\n* Inadequate echocardiographic window preventing reliable assessment","ALL","18 Years",{"count":85,"type":86},30,"ESTIMATED","OBSERVATIONAL","Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.\n\nThis prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.\n\nIn participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.\n\nThe study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.",[90,91,92,93,94,95],"Pulmonary Hypertension (PH)","End Stage Kidney Disease (ESRD)","Hemodialysis Patients","Volume Overload","Volume Assessment","Hemodialysis",[97,95,98,99,93,100,101,102,103,104,105,106],"Pulmonary Hypertension","End-Stage Kidney Disease","Euvolemia","Volume Status","Echocardiography","Bioimpedance Spectroscopy","Interdialytic Weight Gain","Vascular Access","Blood Pressure Variability","Lung Ultrasound","NOT_YET_RECRUITING","2026-06-24",{"date":110,"type":111},"2026-06-30","ACTUAL",{"date":113,"type":86},"2026-07-01",{"date":115,"type":86},"2027-03-30",{"name":67,"class":6},2]